Your browser doesn't support javascript.
loading
Clinical features and outcomes of mpox in people with and without HIV: a national comparative study.
Núñez, Isaac; Ceballos-Liceaga, Santa E; Torre, Alethse de la; García-Rodríguez, Gabriel; López-Martínez, Irma; López-Gatell, Hugo; Mosqueda-Gómez, Juan L; Valdés-Ferrer, Sergio Iván.
Afiliación
  • Núñez I; Department of Medical Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga #15, Belisario Domínguez Sección XVI, Tlalpan, Mexico City, Mexico, 14080. Email: isaac.nunezs@incmnsz.mx. Phone: 5554870900.
  • Ceballos-Liceaga SE; División de Estudios de Posgrado, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
  • Torre A; Dirección General de Epidemiología, Secretaría de Salud, Mexico City, Mexico.
  • García-Rodríguez G; Centro Nacional para la Prevención y el Control del VIH y el sida, Mexican Ministry of Health, Mexico City, Mexico.
  • López-Martínez I; Dirección General de Epidemiología, Secretaría de Salud, Mexico City, Mexico.
  • López-Gatell H; Instituto de Diagnóstico y Referencia Epidemiológicos Dr. Manuel Martínez Báez, Secretaría de Salud, Mexico City, Mexico.
  • Mosqueda-Gómez JL; Secretaría de Salud, Mexico City, Mexico.
  • Valdés-Ferrer SI; Hospital Regional de Alta Especialidad del Bajío, Secretaría de Salud, León, Guanajuato, Mexico.
Article en En | MEDLINE | ID: mdl-38465911
ABSTRACT

BACKGROUND:

People who live with HIV (PWLH) have been one of the most affected groups during the current mpox outbreak. They are hypothesized to have a more severe clinical course than people without HIV but comparative data is scarce. We aimed to compare clinical features and outcomes of mpox in people with and without HIV in Mexico.

SETTING:

Country-wide study in Mexico.

METHODS:

We performed an observational study using nation-wide epidemiological data. We included all people with confirmed mpox diagnosed between May and November 2022 in Mexico. Clinical and sociodemographic characteristics were compared between people with and without HIV. Multivariable logistic regression models were preformed to determine the association between HIV, clinical features, and outcomes and reported with odds ratios (ORs) and 95% confidence intervals (95% CI). ORs for rare outcomes were interpreted as risk ratios.

RESULTS:

Among 3291 people with mpox, 59% were PWLH. PWLH had an increased risk of severe mpox (OR 2.6, 2.4-2.9) and death (OR 10.8, 9.7-11.9). They also had a higher risk of otalgia, proctitis, and urethritis. Eleven individuals died, of whom ten were PWLH. All deaths were directly attributed to mpox.

CONCLUSION:

People with HIV have a higher risk of severe mpox and death due to mpox.

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: J Acquir Immune Defic Syndr Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: J Acquir Immune Defic Syndr Asunto de la revista: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Año: 2024 Tipo del documento: Article